多方法整合构建多扎格列汀生理药代动力学模型
本研究整合异速生长、体外到体内外推与稳态浓度-平均驻留时间方法,构建并验证多扎格列汀的生理药代动力学模型,用单次和多次递增给药研究数据检验,并用于支持药物相互作用研究设计及评估肝硬化和遗传因素对暴露的影响。
要点
- 大鼠与犬两物种异速生长法对中央室清除率预测最佳
- CYP3A4为主要代谢酶,犬药代动力学特征更接近人体
- 模型验证后用于筛选伊曲康唑DDI研究设计并评估内在因素影响
核心结论
- 整合四种方法可从机制层面理解多扎格列汀的药代动力学特征,并成功建立和验证了机制性PBPK模型。
- 该PBPK模型已应用于支持多扎格列汀的临床开发。
研究设计与样本
- 基于临床前体外和体内数据,采用异速生长、体外到体内外推和稳态浓度-平均驻留时间方法分析人体主要药代动力学参数。
- 据此建立初始机制性PBPK模型,用单次递增给药研究观察数据验证并优化,最终模型在进食条件下模拟验证。
- 验证后的模型用于支持临床药物相互作用研究设计,并评估肝硬化与遗传等内在因素对药物暴露的影响。
主要发现
- 采用大鼠和犬数据的两物种异速生长法(TS-rat,dog)是预测人体中央室清除率(CL)的最佳异速生长方法。
- 体外到体内外推确认多扎格列汀主要经细胞色素P450 3A4(CYP3A4)代谢。
- 稳态浓度-平均驻留时间方法提示犬的药代动力学特征与人体更相似。
- 用异速生长和体外到体内外推法估计的CL与观察值差异在1.5倍以内。
- 单次递增给药5-50 mg范围内,模拟Cmax、CL和AUC的90%置信区间落在观察值范围内,模拟tmax的90%置信区间接近观察值。
临床怎么用
- 可依据PBPK模型模拟结果辅助筛选临床DDI研究设计,如选择伊曲康唑作为CYP3A4抑制对象。
- 可利用模型评估肝硬化和遗传因素对多扎格列汀暴露的影响,为特殊人群用药提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The objective of this study was to develop a physiologically based pharmacokinetic (PBPK) model for sinogliatin (HMS-5552, dorzagliatin) by integrating allometric scaling (AS), in vitro to in vivo exploration (IVIVE), and steady-state concentration-mean residence time (Css-MRT) methods and to provide mechanistic insight into its pharmacokinetic properties in humans. METHODS: Human major pharmacokinetic parameters were analyzed using AS, IVIVE, and Css-MRT methods with available preclinical in vitro and in vivo data to understand sinogliatin drug metabolism and pharmacokinetic (DMPK) characteristics and underlying mechanisms. On this basis, an initial mechanistic PBPK model of sinogliatin was developed. The initial PBPK model was verified using observed data from a single ascending dose (SAD) study and further optimized with various strategies. The final model was validated by simulating sinogliatin pharmacokinetics under a fed condition. The validated model was applied to support a clinical drug-drug interaction (DDI) study design and to evaluate the effects of intrinsic (hepatic cirrhosis, genetic) factors on drug exposure. RESULTS: The two-species scaling method using rat and dog data (TS-rat,dog) was the best AS method in predicting human systemic clearance in the central compartment (CL). The IVIVE method confirmed that sinogliatin was predominantly metabolized by cytochrome P450 (CYP) 3A4. The Css-MRT method suggested dog pharmacokinetic profiles were more similar to human pharmacokinetic profiles. The estimated CL using the AS and IVIVE approaches was within 1.5-fold of that observed. The Css-MRT method in dogs also provided acceptable prediction of human pharmacokinetic characteristics. For the PBPK approach, the 90% confidence intervals (CIs) of the simulated maximum concentration (Cmax), CL, and area under the plasma concentration-time curve (AUC) of sinogliatin were within those observed and the 90% CI of simulated time to Cmax (tmax) was closed to that observed for a dose range of 5-50 mg in the SAD study. The final PBPK model was validated by simulating sinogliatin pharmacokinetics with food. The 90% CIs of the simulated Cmax, CL, and AUC values for sinogliatin were within those observed and the 90% CI of the simulated tmax was partially within that observed for the dose range of 25-200 mg in the multiple ascending dose (MAD) study. This PBPK model selected a final clinical DDI study design with itraconazole from four potential designs and also evaluated the effects of intrinsic (hepatic cirrhosis, genetic) factors on drug exposure. CONCLUSIONS: Sinogliatin pharmacokinetic properties were mechanistically understood by integrating all four methods and a mechanistic PBPK model was successfully developed and validated using clinical data. This PBPK model was applied to support the development of sinogliatin.
引用
- Song L, Zhang Y, Jiang J, et al. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics. Clin Pharmacokinet. 2018. PMID: 29626326. doi:10.1007/s40262-018-0631-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。